By Daniella Parra
Lisata Therapeutics (Nasdaq: LSTA), said it has fully enrolled the pancreatic cancer cohort for the CENDIFOX trial.
The company said it evaluates certepetide with FOLFIRINOX therapies in pancreatic, colon, and appendiceal cancers and the trial is being led by Dr. Anup Kasi, who aims to enroll 51 patients and assess the safety and efficacy of this combination therapy, providing crucial tumor data and patient outcomes.
“The successful enrollment of the pancreatic cancer cohort represents another significant step forward in the clinical development of certepetide,” said Dr. Kristen K. Buck, Lisata’s Executive Vice President of Research and Development and Chief Medical Officer. “We are encouraged by the progress of the CENDIFOX trial and look forward to both the completion of enrollment in the remaining two cohorts and the reporting of results.”
Contact:
